ClinicalTrials.gov
public full text
Public Domain
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibodies in diagnosis and screening of HER2-positive cancer patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma#123473
- TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.#1100886
- Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC#160372
- HER2-PET Imaging in HER2-low Breast Cancers#869254
- Targeting of epidermal growth factor receptor (EGFR)-positive pancreatic cancer cell lines with cetuximab-conjugated near-infrared silver sulphide quantum dots#955845
Record · ID 1072363
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive